Your browser doesn't support javascript.
loading
Author Correction: Subgroup analyses from the phase 3 ASCENT study of sacituzumab govitecan in metastatic triple-negative breast cancer.
Hurvitz, Sara A; Bardia, Aditya; Punie, Kevin; Kalinsky, Kevin; Carey, Lisa A; Rugo, Hope S; Diéras, Véronique; Phan, See; Delaney, Rosemary; Zhu, Yanni; Tolaney, Sara M.
Affiliation
  • Hurvitz SA; Clinical Research Division, Department of Medicine, UW Medicine, Fred Hutchinson Cancer Center, Seattle, WA, USA. shurvitz@fredhutch.org.
  • Bardia A; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA.
  • Punie K; Department of General Medical Oncology and Multidisciplinary Breast Centre, Leuven Cancer Institute and University Hospitals Leuven, Leuven, Belgium.
  • Kalinsky K; Winship Cancer Institute, Emory University, Atlanta, GA, USA.
  • Carey LA; University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, NC, USA.
  • Rugo HS; University of California San Francisco, Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, USA.
  • Diéras V; Centre Eugène Marquis, Rennes, France.
  • Phan S; Gilead Sciences Inc., Foster City, CA, USA.
  • Delaney R; Gilead Sciences Inc., Foster City, CA, USA.
  • Zhu Y; Gilead Sciences Inc., Foster City, CA, USA.
  • Tolaney SM; Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
NPJ Breast Cancer ; 10(1): 55, 2024 Jul 09.
Article in En | MEDLINE | ID: mdl-38982075
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: NPJ Breast Cancer Year: 2024 Type: Article Affiliation country: United States
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: NPJ Breast Cancer Year: 2024 Type: Article Affiliation country: United States